Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2008 Jan;28(1):10-2.
doi: 10.1016/j.immuni.2007.12.005.

HIV-1 hides an Achilles' heel in virion lipids

Affiliations
Comment

HIV-1 hides an Achilles' heel in virion lipids

Barton F Haynes et al. Immunity. 2008 Jan.

Abstract

In this issue, Sun et al. (2008) model the interface between a neutralizing antibody and HIV-1 glycoprotein 41 (gp41) envelope peptide in lipids. This model could help overcome a roadblock in HIV-1 vaccine development.

PubMed Disclaimer

Figures

Figure 1
Figure 1. The Three-Step Process of Neutralizing Antibody 4E10 Binding to HIV-1 Envelope Membrane-Proximal Region
According to the model of Sun et al. (2008), the HIV-1 Envelope (HIV-1 Env) gp41 membrane-proximal region in lipids consists of C- and N-terminal helices connected via a short hinge “kink” (represented by the line between each helix) with the N-terminal helix projected away from the membrane and the kink and C-terminal helix bound in lipid. The binding of 4E10 to HIV-1 Env gp41 may occur in three steps. In the first step, interaction of hydrophobic residues of 4E10 CDRH3 (third complementarity-determining region of heavy chain) with membrane lipids concentrates 4E10 in close proximity to HIV-1 Env gp41 membrane-proximal region. In the second step, 4E10 encounters membrane-bound gp41 antigen, which might involve initial contacts with exposed gp41 residues N671 and W680. Next, 4E10 hydrophobic residues (CDRH2 and CDRH3) facilitate conformational rearrangements of the gp41 membrane-proximal region, which involve peptide side-chain rearrangements, and exposure of key residues (W672, F673). Finally, in the third step, stable docking of 4E10 follows insertion of the exposed residues of gp41 into 4E10-binding pocket.

Comment on

Similar articles

Cited by

References

    1. Alam SM, McAdams M, Boren D, Rak M, Scearce RM, Gao F, Camacho ZT, Gewirth D, Kelsoe G, Chen P, Haynes BF. J. Immunol. 2007;178:4424–4435. - PMC - PubMed
    1. Cardoso RM, Zwick MB, Stanfield RL, Kunert R, Binley JM, Katinger H, Burton DR, Wilson IA. Immunity. 2005;22:163–173. - PubMed
    1. Eckert DM, Kim PS. Annu. Rev. Biochem. 2001;70:777–810. - PubMed
    1. Haynes BF, Fleming J, St Clair EW, Katinger H, Stiegler G, Kunert R, Robinson J, Scearce RM, Plonk K, Staats HF, et al. Science. 2005;308:1906–1908. - PubMed
    1. Haynes BF, Montefiori DC. Expert Rev. Vaccines. 2006;5:579–595. - PubMed